Modulation of drug block of the cardiac potassium channel KCNA5 by the drug transporters OCTN1 and MDR1

British Journal of Pharmacology

Volumn 161, Issue 5, 2010, Pages 1023-1033

  Yang, Tao ^a   McBride, Brian F ^a   Leake, Brenda F ^a   Kim, Richard B ^b   Roden, Dan M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WESTERN UNIVERSITY   (Canada)

Author keywords

ABCB1 MDR1; Cardiac KCNA5 K v1.5 channel; Drug block; Drug transporters; OCTN1

Indexed keywords

CIMETIDINE; CLOFILIUM; ERYTHROMYCIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; ORGANIC CATION TRANSPORTER 1; POTASSIUM CHANNEL KV1.5; PROPAFENONE; PROTEIN SERINE THREONINE KINASE INHIBITOR; QUINIDINE; REVERSIN 205; UNCLASSIFIED DRUG; VERAPAMIL; VOLTAGE GATED POTASSIUM CHANNEL;

ANIMAL CELL; ARTICLE; CHO CELL; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TRANSPORT; DRUG UPTAKE; ENZYME SUBSTRATE; GENETIC TRANSFECTION; HEART ATRIUM; HUMAN; MEMBRANE POTENTIAL; NONHUMAN; PHARMACOLOGICAL BLOCKING; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; BINDING SITES; BIOLOGICAL TRANSPORT; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; GENE EXPRESSION REGULATION; HUMANS; KV1.5 POTASSIUM CHANNEL; ORGANIC CATION TRANSPORT PROTEINS; P-GLYCOPROTEIN; PROTEIN BINDING; SWINE;

EID: 77958578543     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00932.x     Document Type: Article

References (38)

1. Alexander SPH, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1): S1-S254.
2. Arias C, Guizy M, David M, Marzian S, Gonzalez T, Decher N et al. (2007). Kvbeta1.3 reduces the degree of stereoselective bupivacaine block of Kv1.5 channels. Anesthesiology 107: 641-651.
3. Chen J, Seebohm G, Sanguinetti MC (2002). Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels. Proc Natl Acad Sci U S A 99: 12461-12466.
4. Decher N, Pirard B, Bundis F, Peukert S, Baringhaus KH, Busch AE et al. (2004). Molecular basis for Kv1.5 channel block - conservation of drug binding sites among voltage-gated K+ channels. J Biol Chem 279: 394-400.
5. Decher N, Kumar P, Gonzalez T, Renigunta V, Sanguinetti MC (2005). Structural basis for competition between drug binding and Kvbeta 1.3 accessory subunit-induced N-type inactivation of Kv1.5 channels. Mol Pharmacol 68: 995-1005.
6. Decher N, Kumar P, Gonzalez T, Pirard B, Sanguinetti MC (2006). Binding site of a novel Kv1.5 blocker: a 'foot in the door' against atrial fibrillation. Mol Pharmacol 70: 1204-1211.
7. Ehrlich JR, Nattel S (2009). Novel approaches for pharmacological management of atrial fibrillation. Drugs 69: 757-774.
8. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. (2006). ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation): Developed in Collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114: e257-e354.
9. Grube M, Meyer zu Schwabedissen HE, Prager D, Haney J, Moritz KU, Meissner K et al. (2006). Uptake of cardiovascular drugs into the human heart: expression, regulation, and function of the carnitine transporter OCTN2 (SLC22A5). Circulation 113: 1114-1122.
10. Hariharan S, Gunda S, Mishra GP, Pal D, Mitra AK (2009). Enhanced corneal absorption of erythromycin by modulating p-glycoprotein and MRP mediated efflux with corticosteroids. Pharm Res 26: 1270-1282.
11. Hylek EM, Regan S, Go AS, Hughes RA, Singer DE, Skates SJ (2001). Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med 135: 393-400.
12. Iwata D, Kato Y, Wakayama T, Sai Y, Kubo Y, Iseki S et al. (2008). Involvement of carnitine/organic cation transporter OCTN2 (SLC22A5) in distribution of its substrate carnitine to the heart. Drug Metab Pharmacokinet 23: 207-215.
13. Khumar P, Gonzalez T, Steinmeyer K, Sanguinetti MC (2004). Overlapping sites for Kv1.5 drug-binding and the receptor site for the Kv beta 1.3 inactivation ball. Biophys J 86: 132A-133A.
14. Kim RB (2002). Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 34: 47-54.
15. Kim RB (2006). Transporters and drug discovery: why, when, and how. Mol Pharm 3: 26-32.
16. Lee W, Kim RB (2004). Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol 44: 137-166.
17. Li GR, Feng J, Wang Z, Fermini B, Nattel S (1996). Adrenergic modulation of ultrarapid delayed rectifier K+ current in human atrial myocytes. Circ Res 78: 903-915.
18. McBride BF, Yang T, Liu K, Urban TJ, Giacomini KM, Kim RB et al. (2009a). The organic cation transporter, OCTN1, expressed in the human heart, potentiates antagonism of the HERG potassium channel. J Cardiovasc Pharmacol 54: 63-71.
19. McBride BF, Yang T, Roden DM (2009b). Influence of the G2677T/C3435T haplotype of MDR1 on P-glycoprotein trafficking and ibutilide-induced block of HERG. Pharmacogenomics J 9: 194-201.
20. Milan DJ, Kim AM, Winterfield JR, Jones IL, Pfeufer A, Sanna S et al. (2009). Drug-sensitized zebrafish screen identifies multiple genes, including GINS3, as regulators of myocardial repolarization. Circulation 120: 553-559.
21. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC (2000). A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A 97: 12329-12333.
22. Nattel S, Yue L, Wang Z (1999). Cardiac ultrarapid delayed rectifiers: a novel potassium current family of functional similarity and molecular diversity. Cell Physiol Biochem 9: 217-226.
23. Perry M, De Groot MJ, Helliwell R, Leishman D, Tristani-Firouzi M, Sanguinetti MC et al. (2004). Structural determinants of HERG channel block by clofilium and ibutilide. Mol Pharmacol 66: 240-249.
24. Rampe D, Murawsky MK (1997). Blockade of the human cardiac K+ channel Kv1.5 by the antibiotic erythromycin. Naunyn Schmiedebergs Arch Pharmacol 355: 743-750.
25. Rampe D, Wible B, Fedida D, Dage RC, Brown AM (1993). Verapamil blocks a rapidly activating delayed rectifier K+ channel cloned from human heart. Mol Pharmacol 44: 642-648.
26. Rezazadeh S, Claydon TW, Fedida D (2006). KN-93 (2-[N-(2-hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinn amyl)-N-methylbenzylamine), a calcium/calmodulin-dependent protein kinase II inhibitor, is a direct extracellular blocker of voltage-gated potassium channels. J Pharmacol Exp Ther 317: 292-299.
27. Riganti C, Campia I, Polimeni M, Pescarmona G, Ghigo D, Bosia A (2009). Digoxin and ouabain induce P-glycoprotein by activating calmodulin kinase II and hypoxia-inducible factor-1alpha in human colon cancer cells. Toxicol Appl Pharmacol 240: 385-392.
28. Savelieva I, Camm J (2008a). Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace 10: 647-665.
29. Savelieva I, Camm J (2008b). Update on atrial fibrillation: part I. Clin Cardiol 31: 55-62.
30. Seebohm G, Pusch M, Chen J, Sanguinetti MC (2003). Pharmacological activation of normal and arrhythmia-associated mutant KCNQ1 potassium channels. Circ Res 93: 941-947.
31. Sharom FJ, Yu X, Lu P, Liu R, Chu JW, Szabo K et al. (1999). Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells. Biochem Pharmacol 58: 571-586.
32. Sikri V, Pal D, Jain R, Kalyani D, Mitra AK (2004). Cotransport of macrolide and fluoroquinolones, a beneficial interaction reversing P-glycoprotein efflux. Am J Ther 11: 433-442.
33. Snyders DJ, Tamkun MM, Bennett PB (1993). A rapidly activating and slowly inactivating potassium channel cloned from human heart. Functional analysis after stable mammalian cell culture expression. J Gen Physiol 101: 513-543.
34. Strutz-Seebohm N, Gutcher I, Decher N, Steinmeyer K, Lang F, Seebohm G (2007). Comparison of potent Kv1.5 potassium channel inhibitors reveals the molecular basis for blocking kinetics and binding mode. Cell Physiol Biochem 20: 791-800.
35. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T et al. (2006). Heart Disease and Stroke Statistics - 2006 Update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113: e85-151.
36. Wang Z, Fermini B, Nattel S (1993). Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents. Circ Res 73: 1061-1076.
37. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M et al. (1999). Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and PH-dependent transport of organic cations. J Pharmacol Exp Ther 289: 768-773.
38. Yeola SW, Rich TC, Uebele VN, Tamkun MM, Snyders DJ (1996). Molecular analysis of a binding site for quinidine in a human cardiac delayed rectifier K+ channel. Role of S6 in antiarrhythmic drug binding. Circ Res 78: 1105-1114.